Want to see NCNA full AI Analyst Report?
Top Page
Nucana
(NASDAQ:NCNA)
Select Model
Select Model
Rating:45Neutral
Price Target:
$1.50
▼(-1.96% Downside)
Action:Reiterated
Date:10/01/26
The score is held down primarily by weak financial performance (no revenue, ongoing losses, and continued cash burn), only partially offset by a low-debt balance sheet and improving burn rate. Technicals are also a headwind with the price below key longer-term moving averages and a negative MACD, while valuation provides limited support due to negative earnings and no dividend.
Positive Factors
Strengthening Intellectual Property
The European composition-of-matter patent strengthens protection for NUC-7738 while the broader estate of more than 85 issued patents supports defensibility. Durable intellectual property can protect future commercialization opportunities and improve the company’s position as clinical development advances.
Negative Factors
No Commercial Revenue
Without an approved commercial product, NuCana lacks recurring product revenue to fund research, development, and administration. Its future financial model therefore depends on successful clinical progress and potential external sources such as financing, licensing payments, milestones, or royalties.
Read all positive and negative factors
Positive Factors
Negative Factors
Strengthening Intellectual Property
The European composition-of-matter patent strengthens protection for NUC-7738 while the broader estate of more than 85 issued patents supports defensibility. Durable intellectual property can protect future commercialization opportunities and improve the company’s position as clinical development advances.
Read all positive factors
Nucana (NCNA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.82M
Dividend YieldN/A
Average Volume (3M)64.58K
Price to Earnings (P/E)―
Beta (1Y)1.38
Revenue GrowthN/A
EPS Growth99.50%
CountryUS
Employees11
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.97
Shares Outstanding4,161,971
10 Day Avg. Volume24,853
30 Day Avg. Volume64,585
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.25
Price to Sales (P/S)0.00
P/FCF Ratio-0.78
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-8
Revenue Forecast (FY)N/A
Nucana Business Overview & Revenue Model
Company Description
NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform. Among its key drug candidates, Acelarin is ...
How the Company Makes Money
NuCana does not have a product approved for commercial sale, so recurring product revenue is null. As a clinical-stage biotechnology company, its ability to generate revenue is primarily tied to non-product sources such as upfront payments, milest...
Nucana Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
35
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -71.37K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -14.37M | -20.56M | -22.48M | -30.55M | -42.98M | -44.42M |
| Net Income | -9.73M | -29.35M | -19.00M | -27.63M | -32.02M | -40.53M |
Balance Sheet | ||||||
| Total Assets | 25.63M | 29.83M | 14.77M | 27.81M | 58.25M | 77.47M |
| Cash, Cash Equivalents and Short-Term Investments | 19.39M | 24.25M | 6.75M | 17.23M | 41.91M | 60.26M |
| Total Debt | 667.94K | 676.00K | 190.00K | 396.00K | 639.00K | 371.00K |
| Total Liabilities | 5.49M | 5.51M | 8.82M | 12.92M | 19.75M | 11.93M |
| Stockholders Equity | 20.14M | 24.33M | 5.95M | 14.89M | 38.50M | 65.55M |
Cash Flow | ||||||
| Free Cash Flow | -5.15M | -7.66M | -19.41M | -26.92M | -23.68M | -24.89M |
| Operating Cash Flow | -4.98M | -7.47M | -19.12M | -26.44M | -23.16M | -23.82M |
| Investing Cash Flow | 236.10K | 159.00K | 79.00K | 2.89M | 120.00K | -3.56M |
| Financing Cash Flow | 15.29M | 25.01M | 8.18M | -53.00K | -161.00K | -98.00K |
Nucana Technical Analysis
Negative
1.53
Price Trends
1.39
Negative
1.57
Negative
2.01
Negative
Market Momentum
-0.05
Positive
37.74
Neutral
32.69
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NCNA, the sentiment is Negative. The current price of 1.53 is above the 20-day moving average (MA) of 1.32, above the 50-day MA of 1.39, and below the 200-day MA of 2.01, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 37.74 is Neutral, neither overbought nor oversold. The STOCH value of 32.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NCNA.
Nucana Risk Analysis
Nucana disclosed 92 risk factors in its most recent earnings report. Nucana reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
We have identified conditions and events that raise substantial doubt about our ability to continue as a going concern, which may hinder our ability to obtain future financing. Q4, 2023
2.
Our internal computer systems, or those of our CROs or other contractors or consultants, may fail or suffer cybersecurity incidents, which could result in a material disruption of our product development programs, and could subject us to liability. Q4, 2023
3.
Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price. Q4, 2023
Nucana Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $9.44M | -0.68 | -46.72% | ― | -99.38% | 53.42% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $8.94M | -3.10 | -31.88% | ― | 10.41% | 42.44% | |
45 Neutral | $5.82M | -0.31 | -41.95% | ― | ― | 99.50% | |
45 Neutral | $5.44M | -1.92 | -40.62% | ― | 33.30% | 40.59% |
* Healthcare Sector Average
NCNA
Nucana
1.17
-3.46
-74.73%
XBIO
Xenetic Biosciences
2.24
-1.05
-31.91%
IMRN
Immuron
1.13
-0.93
-45.15%
APRE
Aprea Therapeutics
0.72
-0.76
-51.15%
Nucana Corporate Events
NuCana Wins Key European Patent for Lead Cancer Drug NUC-7738
Sep 30, 2026
NuCana plc, a clinical-stage biopharmaceutical company based in Edinburgh, develops cancer therapies using its proprietary ProTide technology to enhance existing nucleoside analog chemotherapy agents. Its lead candidates include NUC-7738, a novel ...
NuCana Files Q2 2026 Results and Updates U.S. Registration Statements
Aug 13, 2026
On August 13, 2026, NuCana filed a Form 6-K reporting its unaudited financial results for the quarter and six months ended June 30, 2026, showing continued operating losses driven by research and development and administrative expenses, alongside ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.